Business
Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT® will be Presented at the PCR e-Course, Late Breaking Trial Sessions, June 27, 2020
Medicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT® will be Pr...
About this update from Medicure Inc.
[{"type":"text","content":"\n\n\n\nMedicure Announces Top Line Data from FABOLUS-FASTER Trial With AGGRASTAT® will be Presented at the PCR e-Course, Late Breaking Trial Sessions, June 27, 2020\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prnml40{\nMARGIN-LEFT:3.33em\n}\n\n\n\n\n\n\n\nCanada NewsWire\nWINNIPEG, MB, June 15, 2020\n\n\n\nWINNIPEG, MB, June 15, 2020 /CNW/ - Medicure Inc. (\"Medicure\" or the \"Company\") (TSXV:MPH, OTC:MCUJF), a pharmaceutical company, is pleased to announce that on Saturday, June 27, 2020, Dr. Marco Valgimigli, MD, PhD, Professor of Cardiology, Director of Clinical Research at Bern University Hospital, will present the results of the FABOLUS-FASTER Phase 4 clinical trial. The FABOLUS-FASTER trial was designed to assess different regimens of intravenous platelet inhibitors, notably AGGRASTAT® (tirofiban hydrochloride) injection (an IV GP IIb/IIIa inhibitor) and cangrelor (an IV P2Y12 inhibitor) in the early phase of primary PCI. Dr. Valgimigli's presentation will take place during a late-breaking trial session at the PCR e-Course 2020, on Saturday, June 27 at 9:00 am CET / 3:00 am EDT. \nFABOLUS-FASTER is a randomized, open-label, multi-center trial comparing AGGRASTAT® to cangrelor in patients with ST-elevation myocardial infarction referred for PCI*. A total of 120 subjects were randomized to receive AGGRASTAT®, cangrelor, chewed or integer prasugrel at the beginning of primary PCI. \nPresentation of FABOLUS-FASTER Trial Results by Dr. Marco Valgimigli: 9:00 am CET / 3:00 am EDT on Saturday, June 27 at the PCR e-Course 2020, Late Breaking Trials, Session \"STEMI Interventions: First-In-Man and Novel Pharmacological Strategies\", virtual meeting. To register and participate in the PCR e-Course, click here: https://www.pcronline.com/Courses/PCR-e-Course\nThe content will remain available on replay during and after the e-Course.\nComplete results from this study have been accepted for publication in Circulation, a peer-reviewed journal of the American Heart Association.\nAdditional Details About the Study FABOLUS-FASTER was funded by a grant from ...